Shopping Cart
- Remove All
- Your shopping cart is currently empty
NDB is a selective and potent hFXRα antagonist that inhibits GW4064-stimulated FXR/RXR interactions and FXRα target gene expression in primary mouse hepatocytes.NDB is used in the study of diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $99 | In Stock |
Description | NDB is a selective and potent hFXRα antagonist that inhibits GW4064-stimulated FXR/RXR interactions and FXRα target gene expression in primary mouse hepatocytes.NDB is used in the study of diabetes. |
In vitro | NDB induces rearrangements of helix 11 (H11) and helix 12 (H12, AF-2) by forming a homodimer of hFXRα-LBD, differing significantly from the active monomer conformation[1]. At 25 μM, NDB effectively antagonizes the GW4064-stimulated FXR/RXR interaction and FXRα target gene expression in primary mouse hepatocytes, including the small heterodimer partner (SHP) and bile-salt export pump (BSEP)[1].' |
In vivo | Administered through intraperitoneal injection at a dosage of 24 mg/kg once a day for a duration of 4 weeks, NDB efficiently decreases the gene expressions of phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-phosphatase (G6-pase), small heterodimer partner, and bile-salt export pump (BSEP) in db/db mice[1]. |
Molecular Weight | 471.42 |
Formula | C26H28Cl2N2O2 |
Cas No. | 1660153-08-1 |
Smiles | CN(C)c1cc(Cl)c(C(=O)N(Cc2ccccc2)c2ccc(O)c(c2)C(C)(C)C)c(Cl)c1 |
Storage | store at low temperature | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (169.70 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.